Macrogenics (MGNX) Misses Q3 EPS by 17c

Macrogenics (NASDAQ: MGNX) reported Q3 EPS of ($0.97), $0.17 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $3.3 million versus the consensus estimate of $12.45 million.

Cash, cash equivalents and marketable securities as of September 30, 2016, were $314.1 million, compared to $339.0 million as of December 31, 2015.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.

You May Also Be Interested In

• KB Home (KBH) Tops Q3 EPS by 16c
• Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
• Activist Corvex seeks Whitbread board seat over strategy concerns